Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream in Discoid Lupus Erythematosus
NCT06261021Phase 2Recruiting
- Sponsor
- Innovaderm Research
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ruxolitinib cream in discoid lupus erythematosus (DLE) (2 arms), sponsored by Innovaderm Research. Primary endpoint: Cutaneous Lupus Erythematosus Disease Area and Severity Index - Activity at 24 weeks. Started Apr 2024; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT06261021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261021.